Attitudes of clinicians following large-scale pharmacogenomics implementation

J. F. Peterson, J. R. Field, Y. Shi, J. S. Schildcrout, J. C. Denny, T. L. McGregor, S. L. van Driest, J. M. Pulley, I. M. Lubin, Michael Laposata, D. M. Roden, E. W. Clayton

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Clinician attitudes toward multiplexed genomic testing may be vital to the success of translational programs. We surveyed clinicians at an academic medical center about their views on a large pharmacogenomics implementation, the PREDICT (Pharmacogenomic Resource for Enhanced Decisions in Care and Treatment) program. Participants were asked about test ordering, major factors influencing use of results, expectations of efficacy and responsibility for applying results to patient care. Virtually all respondents (99%) agreed that pharmacogenomics variants influence patients’ response to drug therapy. The majority (92%) favored immediate, active notification when a clinically significant drug–genome interaction was present. However, clinicians were divided on which providers were responsible for acting on a result when a prescription change was indicated and whether patients should be directly notified of a significant result. We concluded genotype results were valued for tailoring prescriptions, but clinicians do not agree on how to appropriately assign clinical responsibility for actionable results from a multiplexed panel.The Pharmacogenomics Journal advance online publication, 11 August 2015; doi:10.1038/tpj.2015.57.

Original languageEnglish (US)
JournalPharmacogenomics Journal
DOIs
StateAccepted/In press - Aug 11 2015

Fingerprint

Pharmacogenetics
Prescriptions
Publications
Patient Care
Genotype
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics

Cite this

Peterson, J. F., Field, J. R., Shi, Y., Schildcrout, J. S., Denny, J. C., McGregor, T. L., ... Clayton, E. W. (Accepted/In press). Attitudes of clinicians following large-scale pharmacogenomics implementation. Pharmacogenomics Journal. https://doi.org/10.1038/tpj.2015.57

Attitudes of clinicians following large-scale pharmacogenomics implementation. / Peterson, J. F.; Field, J. R.; Shi, Y.; Schildcrout, J. S.; Denny, J. C.; McGregor, T. L.; van Driest, S. L.; Pulley, J. M.; Lubin, I. M.; Laposata, Michael; Roden, D. M.; Clayton, E. W.

In: Pharmacogenomics Journal, 11.08.2015.

Research output: Contribution to journalArticle

Peterson, JF, Field, JR, Shi, Y, Schildcrout, JS, Denny, JC, McGregor, TL, van Driest, SL, Pulley, JM, Lubin, IM, Laposata, M, Roden, DM & Clayton, EW 2015, 'Attitudes of clinicians following large-scale pharmacogenomics implementation', Pharmacogenomics Journal. https://doi.org/10.1038/tpj.2015.57
Peterson JF, Field JR, Shi Y, Schildcrout JS, Denny JC, McGregor TL et al. Attitudes of clinicians following large-scale pharmacogenomics implementation. Pharmacogenomics Journal. 2015 Aug 11. https://doi.org/10.1038/tpj.2015.57
Peterson, J. F. ; Field, J. R. ; Shi, Y. ; Schildcrout, J. S. ; Denny, J. C. ; McGregor, T. L. ; van Driest, S. L. ; Pulley, J. M. ; Lubin, I. M. ; Laposata, Michael ; Roden, D. M. ; Clayton, E. W. / Attitudes of clinicians following large-scale pharmacogenomics implementation. In: Pharmacogenomics Journal. 2015.
@article{87091d9a91f24be9847f8c6b4a3517eb,
title = "Attitudes of clinicians following large-scale pharmacogenomics implementation",
abstract = "Clinician attitudes toward multiplexed genomic testing may be vital to the success of translational programs. We surveyed clinicians at an academic medical center about their views on a large pharmacogenomics implementation, the PREDICT (Pharmacogenomic Resource for Enhanced Decisions in Care and Treatment) program. Participants were asked about test ordering, major factors influencing use of results, expectations of efficacy and responsibility for applying results to patient care. Virtually all respondents (99{\%}) agreed that pharmacogenomics variants influence patients’ response to drug therapy. The majority (92{\%}) favored immediate, active notification when a clinically significant drug–genome interaction was present. However, clinicians were divided on which providers were responsible for acting on a result when a prescription change was indicated and whether patients should be directly notified of a significant result. We concluded genotype results were valued for tailoring prescriptions, but clinicians do not agree on how to appropriately assign clinical responsibility for actionable results from a multiplexed panel.The Pharmacogenomics Journal advance online publication, 11 August 2015; doi:10.1038/tpj.2015.57.",
author = "Peterson, {J. F.} and Field, {J. R.} and Y. Shi and Schildcrout, {J. S.} and Denny, {J. C.} and McGregor, {T. L.} and {van Driest}, {S. L.} and Pulley, {J. M.} and Lubin, {I. M.} and Michael Laposata and Roden, {D. M.} and Clayton, {E. W.}",
year = "2015",
month = "8",
day = "11",
doi = "10.1038/tpj.2015.57",
language = "English (US)",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Attitudes of clinicians following large-scale pharmacogenomics implementation

AU - Peterson, J. F.

AU - Field, J. R.

AU - Shi, Y.

AU - Schildcrout, J. S.

AU - Denny, J. C.

AU - McGregor, T. L.

AU - van Driest, S. L.

AU - Pulley, J. M.

AU - Lubin, I. M.

AU - Laposata, Michael

AU - Roden, D. M.

AU - Clayton, E. W.

PY - 2015/8/11

Y1 - 2015/8/11

N2 - Clinician attitudes toward multiplexed genomic testing may be vital to the success of translational programs. We surveyed clinicians at an academic medical center about their views on a large pharmacogenomics implementation, the PREDICT (Pharmacogenomic Resource for Enhanced Decisions in Care and Treatment) program. Participants were asked about test ordering, major factors influencing use of results, expectations of efficacy and responsibility for applying results to patient care. Virtually all respondents (99%) agreed that pharmacogenomics variants influence patients’ response to drug therapy. The majority (92%) favored immediate, active notification when a clinically significant drug–genome interaction was present. However, clinicians were divided on which providers were responsible for acting on a result when a prescription change was indicated and whether patients should be directly notified of a significant result. We concluded genotype results were valued for tailoring prescriptions, but clinicians do not agree on how to appropriately assign clinical responsibility for actionable results from a multiplexed panel.The Pharmacogenomics Journal advance online publication, 11 August 2015; doi:10.1038/tpj.2015.57.

AB - Clinician attitudes toward multiplexed genomic testing may be vital to the success of translational programs. We surveyed clinicians at an academic medical center about their views on a large pharmacogenomics implementation, the PREDICT (Pharmacogenomic Resource for Enhanced Decisions in Care and Treatment) program. Participants were asked about test ordering, major factors influencing use of results, expectations of efficacy and responsibility for applying results to patient care. Virtually all respondents (99%) agreed that pharmacogenomics variants influence patients’ response to drug therapy. The majority (92%) favored immediate, active notification when a clinically significant drug–genome interaction was present. However, clinicians were divided on which providers were responsible for acting on a result when a prescription change was indicated and whether patients should be directly notified of a significant result. We concluded genotype results were valued for tailoring prescriptions, but clinicians do not agree on how to appropriately assign clinical responsibility for actionable results from a multiplexed panel.The Pharmacogenomics Journal advance online publication, 11 August 2015; doi:10.1038/tpj.2015.57.

UR - http://www.scopus.com/inward/record.url?scp=84939128588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939128588&partnerID=8YFLogxK

U2 - 10.1038/tpj.2015.57

DO - 10.1038/tpj.2015.57

M3 - Article

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

ER -